Advanced Filters
noise

Hot Flash Clinical Trials

A listing of Hot Flash medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 364 clinical trials
M Meiping Lu, M.D

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

5 - 17 years of age All Phase 1
K Karine BROCHARD, Docteur

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. …

3 - 18 years of age All Phase 2
H Huiyu Nie

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation of B lymphocytes, which may result in many adverse consequences and even death if not treated actively. Telitacicept, approved conditionally in China in March 2021, is a biologic agent targeting B lymphocyte stimulator (BLyS)and a proliferating inducing ligand …

18 - 75 years of age All Phase 4
A Anna-Karin Tibell, MD

Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture

Dupuytren's contracture (DC) is associated with progressive finger flexion and extension deficit caused by fibrosis in the palm and digits. Treatment options include minimally invasive procedures such as percutaneous needle fasciotomy (PNF) and collagenase clostridium histolyticum injections as well as open fasciectomy. PNF has recently become more popular in Sweden …

18 years of age All Phase N/A

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

This is a multi-center, open-label, phase 1 study.

12 - 17 years of age All Phase 1
H Hongyan Tong

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.

18 - 65 years of age All Phase N/A
Q Qiubai Li, Professor

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

The purpose of the study is to explore the safety and efficacy of CD19 Universal CAR-γδT cells in active severe systemic lupus erythematosus.

18 - 70 years of age All Phase 1/2
H Hongying Yang

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).

18 - 65 years of age All Phase 1
T Tian Liu

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

The purpose of this study was to explore the clinical and immunological efficacy of Telitacicept and low dose IL-2 on systemic lupus erythematosus.

18 - 65 years of age All Phase 3
D Dongbao Dongbao Zhao, Doctor

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with moderate to severe refractory systemic lupus erythematosus (SLE). 9-12 patients are planned to be enrolled in the …

18 - 65 years of age All Phase N/A

Simplify language using AI